Cancer

Title
Comparison of Erlotinib in Combination with Gemcitabine Versus Gemcitabine Alone in Individuals with Pancreatic Cancer that was Removed by Surgery
Trial Number
203024102010
Number of Participants
950
Principal Investigator
Eligibility

Adults (> 18) with histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy.

Patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm (IPMN) are eligible.

Purpose

The purpose of this study is to compare the effects, good and/or bad, of the study drug erlotinib in combination with gemcitabine versus gemcitabine alone for individuals with pancreatic cancer that was removed by surgery.

Enrollment

(708) 327-2831

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.